161 related articles for article (PubMed ID: 18076071)
21. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.
Becker CM; Rohwer N; Funakoshi T; Cramer T; Bernhardt W; Birsner A; Folkman J; D'Amato RJ
Am J Pathol; 2008 Feb; 172(2):534-44. PubMed ID: 18202195
[TBL] [Abstract][Full Text] [Related]
22. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.
Knowles HJ; Tian YM; Mole DR; Harris AL
Circ Res; 2004 Jul; 95(2):162-9. PubMed ID: 15192023
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
[TBL] [Abstract][Full Text] [Related]
24. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells.
Alqawi O; Moghaddas M; Singh G
Prostate Cancer Prostatic Dis; 2006; 9(2):126-35. PubMed ID: 16432534
[TBL] [Abstract][Full Text] [Related]
25. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
[TBL] [Abstract][Full Text] [Related]
29. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
Bäckman U; Christofferson R
Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
[TBL] [Abstract][Full Text] [Related]
30. Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Kang FW; Que L; Wu M; Wang ZL; Sun J
Oncol Rep; 2012 Jul; 28(1):193-9. PubMed ID: 22552321
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of vascular endothelial growth factor release in long-term drug-treated breast cancer via transient receptor potential channel 5-Ca(2+)-hypoxia-inducible factor 1α pathway.
Zhu Y; Pan Q; Meng H; Jiang Y; Mao A; Wang T; Hua D; Yao X; Jin J; Ma X
Pharmacol Res; 2015 Mar; 93():36-42. PubMed ID: 25579062
[TBL] [Abstract][Full Text] [Related]
33. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines.
Blancher C; Moore JW; Talks KL; Houlbrook S; Harris AL
Cancer Res; 2000 Dec; 60(24):7106-13. PubMed ID: 11156418
[TBL] [Abstract][Full Text] [Related]
34. [Effect of dominant negative HIF-1alpha (dn HIF-1alpha) on biological characteristics of uterine cervix cancer cells].
Tang BZ; Zhao FY; Wei T; Mu DZ; Mao M; Fu Q; Zhang L; Qu Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May; 39(3):383-7. PubMed ID: 18575320
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression.
Büchler P; Reber HA; Büchler MW; Friess H; Lavey RS; Hines OJ
Cancer; 2004 Jan; 100(1):201-10. PubMed ID: 14692041
[TBL] [Abstract][Full Text] [Related]
36. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
37. HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo.
Kachamakova-Trojanowska N; Podkalicka P; Bogacz T; Barwacz S; Józkowicz A; Dulak J; Łoboda A
Biochem Pharmacol; 2020 May; 175():113922. PubMed ID: 32205093
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Chen D; Landis-Piwowar KR; Chen MS; Dou QP
Breast Cancer Res; 2007; 9(6):R80. PubMed ID: 18300387
[TBL] [Abstract][Full Text] [Related]
39. Thiol-Activated HNO Release from a Ruthenium Antiangiogenesis Complex and HIF-1α Inhibition for Cancer Therapy.
Silva Sousa EH; Ridnour LA; Gouveia FS; Silva da Silva CD; Wink DA; de França Lopes LG; Sadler PJ
ACS Chem Biol; 2016 Jul; 11(7):2057-65. PubMed ID: 27191177
[TBL] [Abstract][Full Text] [Related]
40. The inhibition of glyceraldehyde-3-phosphate dehydrogenase by nitroxyl (HNO).
Lopez BE; Wink DA; Fukuto JM
Arch Biochem Biophys; 2007 Sep; 465(2):430-6. PubMed ID: 17678614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
